Norway Antifungal Drugs Market Size & Outlook, 2026-2033
- Pharmaceuticals
- Infectious Disease Treatment
- Antifungal Drugs Market Outlook
- Infectious Disease Treatment
Global Market
Related Markets
Ask a question about the antifungal drugs market
Norway antifungal drugs market highlights
- The Norway antifungal drugs market generated a revenue of USD 170.9 million in 2025 and is expected to reach USD 238.4 million by 2033.
- The Norway market is expected to grow at a CAGR of 4.3% from 2026 to 2033.
- In terms of segment, azoles was the largest revenue generating drug class in 2025.
- Echinocandins is the most lucrative drug class segment registering the fastest growth during the forecast period.
Antifungal drugs market data book summary
| Market revenue in 2025 | USD 170.9 million |
| Market revenue in 2033 | USD 238.4 million |
| Growth rate | 4.3% (CAGR from 2026 to 2033) |
| Largest segment | Azoles |
| Fastest growing segment | Echinocandins |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Azoles, Echinocandins, Polyenes, Allylamines |
| Key market players worldwide | Novartis AG ADR, Pfizer Inc, Bayer AG, Sanofi SA, Merck KGaA, Merck & Co Inc, GlaxoSmithKline, Abbott Laboratories, Enzon Pharmaceuticals Inc, Astellas Pharma Inc, Glenmark Pharmaceuticals |
Other key industry trends
- In terms of revenue, Norway accounted for 1.0% of the global antifungal drugs market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Europe, Germany antifungal drugs market is projected to lead the regional market in terms of revenue in 2033.
- UK is the fastest growing regional market in Europe and is projected to reach USD 1,405.2 million by 2033.
Key players, such as Almirall, S.A. are offering late-stage pipeline products for fungal infections, such as onychomycosis. This includes products such as Efinaconazole. The company expects to launch this product in Norway in 2023 after its approval.
Such approvals and launches of novel products in the country are expected to propel its market. The Norwegian Medicines Agency (NoMA) is responsible for the approval of pharmaceutical products in the country.
It overall supervises the production, approval, and marketing of medicines. It also ensures the cost-effectiveness and usage of drugs in the country and further regulates the prices & trade conditions for pharmacies.
No credit card required*
Publish Date: Jan 13, 2026
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antifungal Drugs Market Scope
Antifungal Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| Merck KGaA | View profile | 62,345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | www.emdgroup.com |
| Abbott Laboratories | View profile | 114,000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | www.abbottinvestor.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Sanofi SA | View profile | 87,994 | 46, avenue de la Grande Armée, Paris, France, 75017 | www.sanofi.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
| Bayer AG | View profile | 99,723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | www.bayer.com |
| Enzon Pharmaceuticals Inc | View profile | 1 | 20 Commerce Drive, Suite 135, Cranford, NJ, United States, 07016 | www.enzon.com |
| Astellas Pharma Inc | View profile | 14,484 | 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, 103-8411 | www.astellas.com |
| GlaxoSmithKline | View profile | 10001+ | London, England, United Kingdom, Europe | www.gsk.com |
Norway Antifungal Drugs Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Antifungal Drugs Market Outlook will help companies and investors design strategic landscapes.
Azoles was the largest segment with a revenue share of 49.8% in 2025.
Horizon Databook has segmented the Norway antifungal drugs market based on azoles, echinocandins, polyenes, allylamines covering the revenue growth of each sub-segment from 2021 to 2033.
Key players, such as Almirall, S.A. are offering late-stage pipeline products for fungal infections, such as onychomycosis. This includes products such as Efinaconazole. The company expects to launch this product in Norway in 2023 after its approval.
Such approvals and launches of novel products in the country are expected to propel its market. The Norwegian Medicines Agency (NoMA) is responsible for the approval of pharmaceutical products in the country.
It overall supervises the production, approval, and marketing of medicines. It also ensures the cost-effectiveness and usage of drugs in the country and further regulates the prices & trade conditions for pharmacies.
- Norway Antifungal Drugs Market Drug Class Outlook (Revenue, USD Million , 2021-2033)
- Azoles
- Echinocandins
- Polyenes
- Allylamines
- Others
- Norway Antifungal Drugs Market Indication Outlook (Revenue, USD Million , 2021-2033)
- Dermatophytosis
- Aspergillosis
- Candidiasis
- Others
- Norway Antifungal Drugs Market Dosage Form Outlook (Revenue, USD Million , 2021-2033)
- Oral Drugs
- Ointments
- Powders
- Others
- Norway Antifungal Drugs Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
- Hospital Pharmacies
- Retails Pharmacies
- Others
Reasons to subscribe to Antifungal Drugs Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Antifungal Drugs Market Outlook databook
- Our clientele includes a mix of Antifungal Drugs Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway Antifungal Drugs Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Norway Antifungal Drugs Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Norway Antifungal Drugs Market, 2021-2033 (US$M)
Norway antifungal drugs market statistics, by drug class, 2021-2033 (US$M)
